The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance

McMahon, Moira A.; Jilek, Benjamin L.; Brennan, Timothy; Shen, Lin; Zhou, Yan; Wind‐Rotolo, Megan; Xing, Sifei; Bhat, Shridhar; Hale, Braden; Hegarty, Robert W.; Chong, Curtis R.; Liu, Jun O.; Siliciano, Robert F.; Thio, Chloe L.

doi:10.1056/nejmoa067710

Cited by 254 publications

(169 citation statements)

References 27 publications

(29 reference statements)

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…It is incumbent upon the treating clinician to select a regimen containing agents that have activity against HBV if criteria to treat HBV are present [53]. Tenofovir disoproxil fumarate (TDF), entecavir (ETV), emtricitabine (FTC), and lamivudine (LAM) are nucleotide/nucleoside(s) with activity against both HBV and HIV [55,56]. However, the rate of HBV resistance to lamivudine in HBV/HIV concurrently infected patients is high, reaching 90% at 4 years [57].…”

Section: Treatment Of Hbv/hiv Concurrently Infected Patients With Impmentioning

confidence: 99%

Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B

Chien

2008

Hepatol Int

View full text Add to dashboard Cite

Concurrent hepatitis C virus (HCV), hepatitis delta virus (HDV), or human immunodeficiency virus (HIV) infection with chronic hepatitis B virus (HBV) appears to increase the risk of progressive liver disease including liver cirrhosis and hepatocellular carcinoma. There is a 10% prevalence of HCV infection in chronic HBV or HDV infection. Serological evidence of previous exposure to HBV is found in more than 80% of HIVpositive patients in the high risk group. Notably, the most recently acquired virus tends to suppress the pre-existing virus. In chronic HBV infection acquired perinatally or in early childhood, usually HCV is dominant and may suppress or even displace HBV and HDV. Less frequently, HBV or HDV suppresses HCV. It is generally agreed that the dominant virus should be identified in order to make appropriate treatment decisions. Studies with standard interferon (IFN) to treat patients with HCV dominantly dual HBV/HCV infection have showed only limited virological response. But high dose of IFN has been demonstrated with better response rate. Combined ribavirin with standard or pegylated IFN therapy could achieve a sustained HCV clearance rate comparable with those infected with HCV alone. On the contrary, patients with HBV dominantly dual viral infection might indicate more appropriate addition of lamivudine to IFN than ribavirin. Additionally, patients with concurrent infection of HBV and HDV, IFN seems to be the only effective agent. However, the efficacy of IFN is related to the dose. High dose of IFN [9 MU tiw (thrice per week)] and longer treatment duration (at least 2 years) have been shown to achieve adequate virological response. In patients with concurrently infected HBV and HIV, anti-HBV therapy should be considered for all patients with evidence of liver disease, irrespective of the CD4 cell count. In patients not requiring antiretroviral therapy, HBV therapy should be preferentially based on IFN, adefovir, or telbivudine. In contrast, in patients with CD4 cell counts \350 cells/ll or those already on antiretroviral therapy, agents with double anti-HBV and anti-HIV activity are preferred. At present, the evidence of therapeutic efficacy is not sufficient to make a recommendation in treating patients with dual HBV/HCV or HBV/HDV or HBV/HIV infection. Further studies of the well-designed, larger scale are needed to elucidate the role of different regimens or combination in the treatment of dual viral infection.

show abstract

Section: Treatment Of Hbv/hiv Concurrently Infected Patients With Impmentioning

confidence: 99%

Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B

Chien

2008

Hepatol Int

View full text Add to dashboard Cite

show abstract

“…Entecavir, although previously thought to be devoid of antiretroviral effect, has been found to possess modest anti-HIV activity and can select for HIV rt M184 V [130]. This drug should not be used in the absence of fully suppressive antiretroviral therapy (ART).…”

Section: Hiv Therapy Not Indicatedmentioning

confidence: 99%

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

et al. 2009

View full text Add to dashboard Cite

“…Yine TDF ile birlikte LAM da bir diğer seçeneği oluşturur (51). ETV, böbrek toksisitesi nedeniyle TDF alamayanlarda etkili bir ART'nin yanına ek olarak verilmelidir (52). TDF kullanılamayan durumlarda KHB tedavisi için PegIFN ve ADV kombine edilebilir (53).…”

Section: Hbv Ve Hiv Koinfeksiyonunda Tedaviunclassified

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Mıstık¹,

Aydın²,

Aksoy³

et al. 2015

Klimik Dergisi

View full text Add to dashboard Cite

ÖzetTürk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu, özel konaklarda ve özel durumlarda kronik hepatit yönetimine ilişkin bir uzlaşı raporu hazırlamak üzere bir toplantı düzenlemiştir. Raporda konuyla ilgili literatür ve uluslararası kılavuzlar, hepatit B virusu (HBV) için sırasıyla kompanse ve dekompanse sirozlu hastalarda kronik hepatit B (KHB) tedavisi, karaciğer nakli sonrası HBV infeksiyonunun nüks etmesinden korunma ve nüks gelişen hastalarda tedavi, fülminan hepatit B tedavisi, hemodiyaliz hastalarında KHB teda- AbstractStudy Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis in special hosts and special situations. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as therapy of chronic hepatitis B (CHB) in patients with compensated and decompensated cirrhosis, prevention and therapy of recurrent hepatitis B after liver transplantation, management of fulminant

show abstract

The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance

Cited by 254 publications

References 27 publications

Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B

Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Contact Info

Product

Resources

About